[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336749-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336749-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ercc2-mutations-alter-the-genomic-distribution-pattern-of-somatic-mutations-and-are-independently-prognostic-in-bladder-cancer","ERCC2 mutations alter the genomic distribution pattern of somatic mutations - and are independently prognostic in bladder cancer","","ERCC2 mutations in bladder cancer are linked to cisplatin sensitivity, yet their effects on genome instability and patient prognosis have remained unclear. A reanalysis of 382 whole-genome-sequenced bladder cancers shows that ERCC2 mutations substantially reshape genome-wide patterns of somatic mutations. ERCC2 mutant tumors display altered mutational landscape features, including T[C>T]N enrichment, changed replication-time correlations, and CTCF-cohesin mutation hotspots, enabling prediction of pathogenic ERCC2 mutation status.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ercc2-mutations-alter-the-genomic-distribution-pattern-of-somatic-mutations-and-are-independently-prognostic-in-bladder-cancer/336749/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ercc2-mutations-alter-the-genomic-distribution-pattern-of-somatic-mutations-and-are-independently-prognostic-in-bladder-cancer/336749.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main finding about ERCC2 mutations in bladder cancer?","Question",{"text":63,"@type":64},"ERCC2 mutations substantially alter genome-wide patterns of somatic mutations and act as an independent predictor of prognosis in bladder cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do ERCC2 mutations affect the mutational landscape?",{"text":68,"@type":64},"They shift overall somatic mutation distribution, including T[C>T]N enrichment, altered replication-time correlations, and mutation hotspots at CTCF-cohesin binding sites.",{"name":70,"@type":61,"acceptedAnswer":71},"How is this work used to support clinical relevance?",{"text":72,"@type":64},"The study leverages these genome-wide alterations to build a machine learning model that predicts pathogenic ERCC2 mutations, potentially informing treatment decisions for bladder cancer patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336749,1790154843,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer  \nGraphical abstract  \nHighlights  \nAuthors  \nJayne A. Barbour, Tong Ou, Haocheng Yang, ..., Nikola A. Bowden, Song Wu, Jason W.H. Wong  \nCorrespondence  \n[wusong@szu.edu.cn](wusong@szu.edu.cn) (S.W.), jwhwong@hku.hk (J.W.H.W.)  \nIn brief  \nERCC2 driver mutations in bladder cancer are associated with cisplatinsensitivity, but their effect on genome instability and prognosis has not been clariﬁed. In their recent reanalysis of 382 whole-genome-sequenced bladder cancers, Barbour et al. ﬁnd that ERCC2 mutations cause substantial alterations to genome-wide patterns of somatic mutations.  \nd ERCC2 mutations are an independent predictor of prognosis in bladder cancer  \nd ERCC2 mutant bladder cancer has altered genomic distribution of somatic mutations  \nd CTCF-cohesin binding sites are mutation hotspots in ERCC2 mutant bladder cancer  \nd Somatic mutation distribution distinguishes passenger and driver ERCC2 mutations  \nBarbour et al., 2024, Cell Genomics 4, 100627  \nAugust 14, 2024 ª 2024 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xgen.2024.100627](https://doi.org/10.1016/j.xgen.2024.100627)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nERCC2 mutations alter the genomic distribution pattern of somatic mutations  \nand are independently prognostic in bladder cancer  \nJayne A. Barbour,1 Tong Ou,2 Haocheng Yang,1 Hu Fang,1,3 Noel C. Yue,1 Xiaoqiang Zhu,1 Michelle W. Wong-Brown,4,5 Yuen T. Wong,6 Nikola A. Bowden,4,5 Song Wu,2,7,* and Jason W.H. Wong1,8,9,10,*  \n1School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China  \n2Urology Institute of Shenzhen University, The Third Afﬁliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China  \n3Institute of Biomedical Data, South China Hospital, Medical School, Shenzhen University, Shenzhen, China  \n4Centre for Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, NSW, Australia  \n5Hunter Medical Research Institute, Newcastle, NSW, Australia  \n6Adult Cancer Program, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia  \n7Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China  \n8Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong SAR, China  \n9Centre for PanorOmic Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR, China  \n10Lead contact  \n*[Correspondence:](Correspondence: wusong@szu.edu.cn)[ wusong@szu.edu.cn](Correspondence: wusong@szu.edu.cn) (S.W.), jwhwong@hku.hk (J.W.H.W.) [https://doi.org/10.1016/j.xgen.2024.100627](https://doi.org/10.1016/j.xgen.2024.100627)  \nSUMMARY  \nExcision repair cross-complementation group 2 (ERCC2) encodes the DNA helicase xeroderma pigmentosum group D, which functions in transcription and nucleotide excision repair. Point mutations in ERCC2 are putative drivers in around 10% of bladder cancers (BLCAs) and a potential positive biomarker for cisplatin therapy response. Nevertheless, the prognostic signiﬁcance directly attributed to ERCC2 mutations and its pathogenic role in genome instability remain poorly understood. We ﬁrst demonstrated that mutant ERCC2 isan independent predictor of prognosis in BLCA. We then examined its impact on the somatic mutational landscape using a cohort of ERCC2 wild-type (n = 343) and mutant (n = 39) BLCA whole genomes. The genomewide distribution of somatic mutations is signiﬁcantly altered in ERCC2 mutants, including T[C>T]N enrichment, altered replication time correlations, and CTCF-cohesin binding site mutation hotspots. We leverage these alterations to develop a machine learning model for predicting pathogenic ERCC2 mutations, which may be useful to inform treatment of patients with BLCA.  \nINTRODUCTION  \nExcision repair cross-complementation group 2 (ERCC2) encodes xeroderma pigmentosum group D (XPD), a 50","cbCaicAnx0uj5gUn","https://ap.wps.com/l/cbCaicAnx0uj5gUn","pdf",5443088,18,"English","# Summary\n# Introduction\n## ERCC2 function and relevance to bladder cancer\n## Cisplatin sensitivity and clinical prognostic context\n## Knowledge gap and study aim","[{\"question\":\"What is the main finding about ERCC2 mutations in bladder cancer?\",\"answer\":\"ERCC2 mutations substantially alter genome-wide patterns of somatic mutations and act as an independent predictor of prognosis in bladder cancer.\"},{\"question\":\"How do ERCC2 mutations affect the mutational landscape?\",\"answer\":\"They shift overall somatic mutation distribution, including T[C\\u003eT]N enrichment, altered replication-time correlations, and mutation hotspots at CTCF-cohesin binding sites.\"},{\"question\":\"How is this work used to support clinical relevance?\",\"answer\":\"The study leverages these genome-wide alterations to build a machine learning model that predicts pathogenic ERCC2 mutations, potentially informing treatment decisions for bladder cancer patients.\"}]","ERCC2 mutations alter the genomic distribution pattern of somatic mutations - and are independently prognostic in bladder cancer | PDF",1790016450,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/936c8137627d7c68f9aee708a9d7dde1.webp",983,1276,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4a0c896139d041623f0a4da347db685.webp",982,1275,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfaf21255f9bd126fcf0fe2f2a44fe5d.webp",981,1273,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd84aa73820c4ce78d14e5bd6d75f52b.webp",980,1272]